Sort
261,768 grants matching “gene therapy”
Personalized cancer models to discover and develop new therapeutic targets.
$902,672Christopher J Kemp · Fred Hutchinson Cancer Research Center · U01 · FY2017 · CA
SBIR Phase II: Non-Chromatographic Method for the Purification of Viral Vectors
$902,504Kelli M Luginbuhl · Isolere Bio, Inc · · FY2022 · TIP
Antifibrotic Therapy for Chronic Kidney Disease
$902,494Prakash Narayan · Angion Biomedica Corporation · R44 · FY2012 · DK
Targeting undruggable RAS for cancer treatment
$902,485Channing J Der · Univ Of North Carolina Chapel Hill · R35 · FY2023 · CA
ALZHEIMERS RESEARCH PROJECT: Alzheimer's disease drug development
$902,370Nigel H. Greig · National Institute On Aging · ZIA · FY2024 · AG
Ataxin-2 complex proteins in neurodegeneration.
$902,343Stefan M. Pulst · University Of Utah · R35 · FY2024 · NS
SPORE in Pancreatic Cancer
$902,341University Of Alabama At Birmingham · P20 · FY2004 · CA
Nonhuman Primate Antibody Resource for Immune Cell Depletion
$902,336Diogo Magnani · Univ Of Massachusetts Med Sch Worcester · P40 · FY2025 · OD
Cancer Etiology, Prevention, Detection and Diagnosis
$902,334Amato J. Giaccia · Stanford University · T32 · FY2007 · CA
Heritable Disorders Of Connective Tissue
$902,296Joan C Marini · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · Z01 · FY2008 · HD
Multi-Site Validation of Biomarkers and Core Clinical Outcome Measures for Clinical Trials Readiness in CDKL5 Deficiency Disorder
$902,257Timothy A Benke · University Of Colorado Denver · U01 · FY2023 · NS
Physiology, Psychology, and Genetics of Obesity
$902,017Jack A. Yanovski · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2013 · HD
Cell type selective viral tools to interrogate and correct non-human primate and human brain circuitry
$901,932Jonathan T Ting · Allen Institute · UH3 · FY2024 · MH
Dissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complex
$901,706Barry Neal Kreiswirth · Hackensack University Medical Center · R01 · FY2025 · AI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
$901,656Robert C Bast · University Of Tx Md Anderson Can Ctr · P50 · FY2015 · CA
Pacific Ovarian Cancer Research Consortium
$901,655Charles Drescher · Fred Hutchinson Cancer Research Center · P50 · FY2015 · CA
Ebola Vaccine Development
$901,608Nancy J Sullivan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Marburg Vaccine Development
$901,608Nancy J Sullivan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Targeted Nanoparticles for Tempospatially Controlled Combination Chemotherapy
$901,531Robert S Langer · Massachusetts Institute Of Technology · U54 · FY2010 · CA
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$901,490Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2015 · AI
Preclinical characterization of a novel neuropeptide for inducing "on-demand" voiding
$901,425Edward Burgard · Dignify Therapeutics, Llc · U44 · FY2019 · NS
Development of a radiation-activatable nanoparticle for lung cancer therapy
$901,390Jin Xie · Athna Biotech, Inc. · R42 · FY2025 · CA
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$901,309Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2022 · CA
Mosaic: post-zygotic mutations in vascular malformations
$901,287James T Bennett · Seattle Children'S Hospital · R01 · FY2021 · HL
Cellular Regulation in Genitourinary Development
$901,268University Of Virginia Charlottesville · P50 · FY2004 · DK